Basic Study
Copyright ©The Author(s) 2020.
World J Gastrointest Pathophysiol. Mar 13, 2020; 11(1): 1-19
Published online Mar 13, 2020. doi: 10.4291/wjgp.v11.i1.1
Figure 2
Full Size Figure Download Figure
Figure 2 Antagonizing effect of BPC 157 on portal and caval hypertension, and aortal hypotension. Portal, caval and aortal pressure (mmHg), mean ± SD. For portal vein, vena cava, and abdominal aorta pressure recordings, medication of BPC 157 [10 µg/kg (Bµg), 10 ng/kg (Bng)] or saline (5 mL/kg; control) was applied in rats intragastrically or as an abdominal bath, at 15 min (white bars), 24 h (black bars) or 48 h (gray bars) post-ligation. aP < 0.05 vs control.
  • Citation: Gojkovic S, Krezic I, Vrdoljak B, Malekinusic D, Barisic I, Petrovic A, Horvat Pavlov K, Kolovrat M, Duzel A, Knezevic M, Kasnik Kovac K, Drmic D, Batelja Vuletic L, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P. Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats. World J Gastrointest Pathophysiol 2020; 11(1): 1-19
  • URL: https://www.wjgnet.com/2150-5330/full/v11/i1/1.htm
  • DOI: https://dx.doi.org/10.4291/wjgp.v11.i1.1